Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

Scholar Rock Holding (($SRRK)) has held its Q1 earnings call. Read on for the main highlights of the call. Scholar Rock’s latest earnings call stru...

Scholar Rock Charts High-Stakes Path to SMA Launch

Citi analyst Geoff Meacham maintained a Buy rating on Scholar Rock Holding on May 7 and set a price target of $58.00. The company’s shares closed l...

Citi Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Scholar Rock Holding on May 8 and set a price target of $58.00. The comp...

Bank of America Securities Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)

In a report released today, Gary Nachman from Canaccord Genuity maintained a Buy rating on Scholar Rock Holding, with a price target of $62.00. Acc...

Canaccord Genuity Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Scholar Rock Holding today and set a price target of $65.00. According to TipRanks, Ka...

Evercore ISI Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)

Barclays analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding today and set a price target of $55.00. Darout covers the Healthcare ...

Barclays Remains a Buy on Scholar Rock Holding (SRRK)

Scholar Rock Holding ( ($SRRK) ) has shared an announcement. Scholar Rock on May 7, 2026 reported first-quarter 2026 results and recent milestones,...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$51.51	+7.02%	2.65M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$51.51	+7.0%	2.65M
3
4
5
6

SRRK

SRRK

Dividend Overview

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel